Table 2 Summary of findings from gene list comparison and list of most commonly listed genes
From: Heterogeneity in clinical sequencing tests marketed for autism spectrum disorders
Key findings | ||
● Number of genes included on ASD gene sequencing panels ranged from 11 to 2562 ● 2928 unique genes identified across 21 labs ● When comparing the gene lists of 21 labs (see Supplementary Table S1) ○ Only one gene (MECP2) was shared by all labs ○ 63 genes shared by at least 10/21 labs ○ Two sets of labs had the same gene lists ● Of the top 16 genes shared by 16 or more panels, ○ 12 were associated with known OMIM syndromesa primarily involving physical/systemic features, of which 3 (MECP2, PTEN, and CNTNAP2) included autism susceptibility ○ 4 (NLGN4X, PTCHD1, NLGN3, and FOXP1) were associated with primarily a neurocognitive presentation (ASD, intellectual disability) in OMIM ○ 2 (UBE3A and SHANK3) overlapped with known ASD-associated CNV regions ● The top 178 genes shared across 21 labs did NOT include 39 genes cited on 2 or more ASD gene listsc | ||
Top shared genesb | ||
Gene name | Labs | OMIM gene association (OMIM#) a |
MECP2 c | 21/21 | Encephalopathy (300673); Mental retardation (300260)(300055); Rett syndrome (312750); Autism susceptibility (300496) |
NLGN4X | 20/21 | Mental retardation (300495); Asperger syndrome susceptibility (300497); Autism susceptibility (300495) |
CACNA1C c | 19/21 | Brugada syndrome 3 (611875); Timothy syndrome (601005) |
NRXN1 c | 19/21 | Pitt-Hopkins-like syndrome 2 (614325); Schizophrenia susceptibility (614332) |
PCDH19 | 19/21 | Epileptic encephalopathy (300088) |
PTCHD1 c | 19/21 | Autism susceptibility (300830) |
UBE3A | 19/21 | Angelman syndrome (105830) |
NLGN3 c | 18/21 | Asperger syndrome susceptibility (300494); Autism susceptibility (300425) |
PTEN c | 18/21 | Bannayan-Riley-Ruvalcaba syndrome (153480); Cowden syndrome 1/ Lhermitte-Duclos syndrome (158350); Macrocephaly/autism syndrome (605309); VATER association with macrocephaly and ventriculomegaly (276950); Glioma susceptibility (613028); Meningioma (607174); Prostate cancer (176807) |
SHANK3 c | 18/21 | Phelan-McDermid syndrome (606232); Schizophrenia (613950) |
CDKL5 c | 17/21 | Epileptic encephalopathy (300672) |
CNTNAP2 | 17/21 | Cortical dysplasia-focal epilepsy syndrome/ Pitt-Hopkins like syndrome 1 (610042); Autism susceptibility (612100) |
DHCR7 c | 17/21 | Smith-Lemli-Opitz syndrome (270400) |
FOXP1 c | 17/21 | Mental retardation with language impairment and with or without autistic features (613670) |
NSD1 c | 17/21 | Leukemia (601626); Sotos syndrome 1 (117550) |
ARX c | 16/21 | Epileptic encephalopathy (308350); Hydranencephaly with abnormal genitalia (300215); Lissencephaly (300215); Mental retardation (300419); Partington syndrome (309510); Proud syndrome (300004) |